- EQT Private Equity to Acquire SPT Labtech, a Manufacturer and Designer of Automated Instruments and Consumables for Life Science Research Focused on Liquid Handling, Sample Management and Electron Microscopy Sample Preparation Technologies cryogenic (“Cryo-EM”)
- SPT Labtech’s products support cutting-edge life science research, delivering agility, efficiency and productivity for a wide range of applications; SPT Labtech products help accelerate the search for new and breakthrough therapies
- EQT Private Equity will support the next phase of growth for SPT Labtech by focusing on continued product innovation, scaling the Cryo-EM sample preparation segment and expanding the business in new and existing geographies
EQT is pleased to announce that the EQT IX fund (“EQT Private Equity”) has agreed to acquire SPT Labtech (“SPT” or the “Company”) from
Based in Melbourne,
Backed by strong secular megatrends, SPT presents a highly thematic investment opportunity in EQT’s priority Life Science Tools sub-sector. Research automation, miniaturization trends (more analyzes with the same sample volume), and wider adoption of multi-omics will support SPT’s core liquid handling business for years to come. .
Cryo-EM is a state-of-the-art technique supporting the search for new drug targets in new modalities such as cell and gene therapy, as well as mRNA, with the company’s addressable instruments and consumables market expected to grow by 35 to 40 % in the future.
SPT is the leader in resilient and fast-growing market niches, including its core segment, the low-flow liquid handling market, with future market growth forecast at 9-10% CAGR.
SPT helps researchers save time through automation and enables laboratories to research, for example, chronic diseases and provide treatments or find cures for previously incurable conditions. The Company’s core values are closely aligned with the
Under the ownership of EQT Private Equity, the company will benefit from EQT’s strong network of advisors and experts as well as the in-house digital team. EQT will further support the company in new product innovation, expansion into existing and new geographies and end markets (e.g., restoring the in vitro diagnostics market, doubling APAC, and accelerating of Cryo-EM) as well as selective mergers and acquisitions to further strengthen SPT’s position in the market.
EQT Private Equity was advised by Evercore (M&A), Kirkland & Ellis (Legal), Deloitte (Finance & Tax), BCG (Commercial), Ringstone (Technology) and
With this transaction, EQT IX is expected to be 85-90% invested (including closed and/or signed investments, announced public offerings, if any, and less any expected syndication).
EQT Press Office, [email protected], +46 8 506 55 334
About the EQT
EQT is a global, goal-oriented investment organization with
About SPT Labtech
SPT Labtech manufactures products that transform the way scientists work. For nearly two decades, our expert scientists, engineers and business innovators have created innovative solutions for liquid handling, sample preparation and sample management that help accelerate research and make a real difference to human health. We work collaboratively with our customers, building trusted relationships that allow us to deliver exceptional, personalized experiences designed for real-world challenges in the lab.
More information: www.sptlabtech.com
Battery partners with exceptional founders and management teams who are building category-defining businesses in markets such as software and services, enterprise infrastructure, consumer technology, healthcare IT and industrial technology. Founded in 1983, the firm supports businesses at all stages, from seed and start-up to growth and buyout, and invests globally from offices to
More information: www.battery.com
(c) Decision 2022. All rights reserved., sources